Tag Archives: oxford

Breast screening for over 70s doesn’t prompt sharp fall in advanced disease, study suggests

Their paper publishes as the Preventing Overdiagnosis conference opens next week where experts from around the world will discuss how to tackle the threat to health and the waste of money caused by unnecessary care. The conference is hosted by the Centre for Evidence-Based Medicine at the University of Oxford in partnership with The BMJ’s Too Much Medicine campaign. The upper age limit for the national breast cancer screening program was extended to women aged 69 to 75 in 1998 in the Netherlands, and national guidelines now recommend screening women up to the age of 75. …

Soy supplementation adversely effects expression of breast cancer-related genes — ScienceDaily

The impact of soy consumption on breast cancer prevention and treatment is not clear although many women believe soy supplementation is beneficial based primarily on results from epidemiological studies. Moshe Shike, M.D., from the Department of Medicine at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College in New York, NY, and colleagues conducted a randomized placebo-controlled study of the effects of soy supplementation on gene expression and markers of breast cancer risk among women diagnosed with invasive breast cancer. The study, run between 2003 and 2007 at Memorial Sloan-Kettering, enrolled a total of 140 patients who were randomized to either soy supplementation (soy protein) or placebo (milk protein), which lasted from the initial surgical consultation to the day before surgery (range=7-30 days)…

Soy supplementation adversely effects expression of breast cancer-related genes

The impact of soy consumption on breast cancer prevention and treatment is not clear although many women believe soy supplementation is beneficial based primarily on results from epidemiological studies. Moshe Shike, M.D., from the Department of Medicine at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College in New York, NY, and colleagues conducted a randomized placebo-controlled study of the effects of soy supplementation on gene expression and markers of breast cancer risk among women diagnosed with invasive breast cancer. The study, run between 2003 and 2007 at Memorial Sloan-Kettering, enrolled a total of 140 patients who were randomized to either soy supplementation (soy protein) or placebo (milk protein), which lasted from the initial surgical consultation to the day before surgery (range=7-30 days). Tumor tissues from the diagnostic biopsy (pre-treatment) and at the time of resection (post-treatment) were then analyzed. …

Are you as old as what you eat? Researchers learn how to rejuvenate aging immune cells

The two new studies, supported by the Biotechnology and Biological Sciences Research Council (BBSRC), could help to enhance our immunity to disease through dietary intervention and help make existing immune system therapies more effective. As we age our immune systems decline. Older people suffer from increased incidence and severity of both infections and cancer…

Rates of heart disease, stroke continue to decline in Europe

The research, which provides an update for 2014 on the burden of cardiovascular disease (CVD) in Europe, shows that death rates from CVD (diseases of the heart and blood vessels) vary enormously. For some eastern European countries, including Russia and Ukraine, the death rate from coronary heart disease for 55-60 year olds is greater than the equivalent rate in France for people 20 years older. The age adjusted CVD death rates for men and women of all ages were six-fold higher in Russia than in France. In 2010 in Russia 915 men and 517 women died per 100,000 of the population, whereas the equivalent rates in France were 150 and 87 per 100,000 respectively. …

Marginal life expectancy benefit from contralateral prophylactic mastectomy — ScienceDaily

To assess the survival benefit of CPM, Pamela R. Portschy, of the Department of Surgery, University of Minnesota, Minneapolis, and colleagues, developed a model simulating survival outcomes of CPM or no CPM for women with newly diagnosed stage I or II breast cancer, using data from the Surveillance, Epidemiology, and End Results (SEER) registry and large meta-analyses. Survival benefit projections were made for women by age (40, 50, or 60 years), breast cancer stage (I or II), and estrogen receptor (ER) status (positive or negative). Women with BRCA mutations were excluded from the analysis because they have a much higher risk of developing contralateral breast cancer. …

Screening costs increased in older women without changing detection rates of early stage breast cancer — ScienceDaily

The effect of introduction of new breast cancer screening modalities, such as digital images, computer-aided detection (CAD), and use of ultrasound and MRI on screening costs among older women is unknown, although women over the age of 65 represent almost one-third of the total women screened in the US annually. …